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human osteoarthritic chondrocytes and
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Background: Intra-articular hyaluronan (HA) injection provides symptomatic benefit in the treatment of
osteoarthritis (OA). Previously we found superior beneficial effects in a large animal OA model of a hexadecylamide
derivative compared with unmodified HA of the same initial molecular weight. The current study sought to define
possible molecular mechanisms whereby this enhanced relief of symptoms was occurring.
Methods: Chondrocytes and synovial fibroblasts were isolated from tissues of patients undergoing arthroplasty for
knee OA. Monolayer cultures of cells were treated with 0, 0.5, 1.0 or 1.5 mg/mL of unmodified HA (500–730 kDa) or
a hexadecylamide derivative of HA of the same initial molecular weight (HYADD4®-G; HYMOVIS®) simultaneously or
1 hour before incubation with interleukin (IL)-1beta (2 ng/mL). Cultures were terminated 15 or 30 minutes later
(chondrocytes and synovial fibroblasts, respectively) for quantitation of phosphorylated-(p)-JNK, p-NFkappaB, p-p38,
or at 24 hours for quantitation of gene expression (MMP1 & 13, ADAMTS4 & 5, TIMP1 & 3, CD44, COL1A1 & 2A1,
ACAN, PTGS2, IL6, TNF) and matrix metalloproteinase (MMP)-13 activity.
Results: The hexadecylamide derivative of HA had significantly better amelioration of IL-1beta-induced gene
expression of key matrix degrading enzymes (MMP1, MMP13, ADAMTS5), and inflammatory mediators (IL6, PTGS2) by
human OA chondrocytes and synovial fibroblasts. Pre-incubation of cells with the derivatized HA for 1 hour prior to
IL-1beta exposure significantly augmented the inhibition of MMP1, MMP13, ADAMTS4 and IL6 expression by
chondrocytes. The reduction in MMP13 mRNA by the amide derivative of HA was mirrored in reduced MMP-13
protein and enzyme activity in IL-1beta-stimulated chondrocytes. This was associated in part with a greater
inhibition of phosphorylation of the cell signalling molecules JNK, p38 and NF-kappaB.
Conclusions: The present studies have demonstrated several potential key mechanisms whereby the intra-articular
injection of a hexadecylamide derivative of HA may be acting in joints with OA.
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Osteoarthritis (OA) is characterized by joint pain and
stiffness with accompanying disability and loss of quality
of life. All joint tissues, including capsule, synovium,
intra-articular ligaments and menisci, bone and cartilage
are affected in OA. The articular cartilage within affected
joints is eventually degraded and lost, thus ceasing to
function as a frictionless bearing surface. While it is the ul-
timate loss of cartilage that often necessitates the need for
joint replacement, it is subchondral bone lesions and syn-
ovial/joint capsule inflammation and fibrosis that appear
to be primarily responsible for OA pain [1]. Current treat-
ments for OA are limited and are either pain-relieving or
involve joint replacement at end-stage disease. There are
no treatments available that have been unequivocally
demonstrated to exhibit structural modification to restore
function.
Hyaluronan (HA), a macromolecular glycosaminogly-
can, is a major component of both synovial fluid and
articular cartilage. Treatment of OA with intra-articular
HA is a current alternative treatment to NSAIDs or
other palliative pain medications and a number of clin-
ical trials have been performed with different HA prod-
ucts. Recent meta-analyses have concluded that HA is of
a longer-term symptomatic benefit than other treat-
ments, with a clinically relevant effect size equivalent or
greater than other analgesics [2,3]. Despite this evidence,
the mechanism(s) by which HA alleviates joint pain re-
mains unclear. Intra-articular HA therapy can lead to
modulation of nociceptors [4], reduction of synovial/cap-
sular fibrosis [5], increased synthesis of higher molecular
weight endogenous HA by the resident synoviocytes
[5,6], and reduction in inflammatory mediators including
prostaglandin-E2, IL-1 and IL-6 [7-9]. There is signifi-
cant evidence that intra-articular HA injection reduces
the rate of cartilage degeneration in animal models of
OA [10,11] (and reviewed in [4,12]) but whether the same
is true in humans is unclear. Amelioration of cartilage
breakdown by HA is thought to occur through enhance-
ment of chondrocyte aggrecan synthesis [13,14], reduction
of matrix degrading enzyme (matrix metalloproteinases
(MMPs) [15] and disintegrin and metalloproteinase with
thrombospondin motifs (ADAMTS) [16]), and modifica-
tion of inflammatory cytokine expression and activity [4].
The latter also being implicated in symptom modification.
The effectiveness of intra-articular HA on both symp-
tomatic and structural modification in pre-clinical OA
models, appears to be dependent, at least in part, on its
MW [17,18].
Previously we found superior beneficial effects of
intra-articular injection of a hexadecylamide derivative
of HA (HYADD4®-G; HYMOVIS®) compared with un-
modified 500–730 kDa HA, on gait analysis, stimulation
of synoviocyte high MW HA synthesis, and reduction insynovial hyperplasia in model of established OA in sheep
[5,19]. The current study investigated the potential mech-
anisms whereby HA might be acting using human joint
tissue cells, and whether these differed between the amide
derivative and unmodified HA preparations. We found a
significantly greater effect of the hexadecylamide deriva-
tive of HA in ameliorating IL-1-induced expression and/
or activity of key matrix degrading enzymes (MMP1,
MMP13, ADAMTS5), and inflammatory mediators (IL6,
PTGS2) by chondrocytes and synovial fibroblasts. This
was associated in part with a greater inhibition of cell sig-
nalling molecule (JNK, p38 and NFκB) phosphorylation in
chondrocytes, together suggesting mechanisms whereby
the hexadecylamide derivative of HA may be beneficial.
Methods
Ethics
Ethics approval was obtained from North Shore Central
Coast Area Health and Ramsey Health to collect discarded
human joint tissue from OA patients undergoing total or
partial knee replacement surgery at Royal North Shore
Hospital and North Shore Private Hospital respectively
(Northern Sydney Central Coast Health 0902-034 M,
NSW Health). The protocol required written patient
consent and was managed through the Department of
Orthopaedics and Traumatic Surgery at Royal North
Shore Hospital.
Patient demographics
Tissues (either synovium or articular cartilage) were
harvested from a total of 19 patients (9 male, 10 female;
7 HSF and 12 HAC) with a mean age of 70 years (range
55 – 86). All patients except one were undergoing either
a unilateral or bilateral total knee replacement; the youn-
gest patient had a partial replacement.
Cell isolation and culture
Human articular chondrocytes (HAC) were isolated
from articular cartilage and synovial fibroblasts (HSF)
from synovium by proteolytic digestion using established
methods [6,20]. All HSF were cryopreserved before use;
all HAC were used immediately after isolation at the pri-
mary passage. Cells were cultured in monolayer in DMEM
(HSF) or DMEM/F12 (HAC) media supplemented with
10% (v/v) foetal bovine serum (FBS), 2 mM glutamine to
confluence after seeding at 300,000 cells/well in 6-well
plates. Primary chondrocytes were used immediately after
isolation from tissue digests to avoid any loss of matrix ex-
pression due to dedifferentiation [21] and fibroblasts were
used at the 6th to 10th passage. Cells from at least 5 differ-
ent patients in triplicate wells per condition were used for
each experiment.
After reaching confluence, cells were washed with
serum free media and then cultured for 24 hours in fresh
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acclimatization. Fresh media containing unmodified or
the hexadecylamide derivative of HA (0, 0.5, 1, and
1.5 mg/mL) was added and cells cultured with either
simultaneous addition or delayed (after one hour pre-
incubation with HA) addition of recombinant IL-1β
(2 ng/mL). Cultures were terminated at different time
points after the addition of IL-1β depending on the out-
come measure: 1) 24 hours for gene expression analysis
and enzyme activity or 2) 15 minutes (HAC) or 30 mins
(HSF) for phosphoprotein Bio-plex analysis (see below).
In HSF from 1 patient and HAC from 2 patients,
CD44 antibody (R&D systems BBA10; 5 or 10 μg/mL) or
IgG isotype control antibody at the same concentration
(R&D Systems MAB003) were added to the cultures 1 or
3 hours before the addition of the hexadecylamide deriva-
tive of HA (HYADD4®-G; HYMOVIS® at 0.5 mg/ml), ±
IL-1β (2 ng/mL) one hour later, as previously described
[22]. These cultures (n = 6 replicates for each treatment in
each patient) were terminated at 24 hours for gene expres-
sion analysis.
Preparation of HA media solutions
Unmodified HA (500–730 kDa 10 mg/ml in 2 ml sterile
syringe) and a hexadecylamide derivative of HA of the
same initial molecular weight (HYADD®4-G; HYMOVIS®;
8 mg/ml in 3 ml sterile syringe) of the same purity were
supplied by Fidia Farmaceutici SpA. For treatment of each
cell type from each patient, 3 mg/ml solutions of un-
modified or the hexadecylamide derivative of HA in
appropriate 1× culture media (6 ml HYMOVIS® + 2 ml
sterile H2O or 4.8 ml unmodified HA + 3.2 ml H2O;
added to 8 ml 2× culture media) were freshly prepared the
day before and very gently rotated overnight at 4°C to
ensure a homogeneous solution. This procedure is necessary
due to the high viscosity of these solutions. These 3 mg/ml
stocks of HA were then appropriately diluted in media
to the physiologically relevant concentrations of 1.5, 1.0
and 0.5 mg/ml [23].
RNA extraction, reverse transcription and real time PCR
At the termination of culture, cells for RNA extraction
were rinsed twice gently with phosphate buffer saline
pH 7.2 and then removed from the wells using 0.75 mL
TRIzol®. Total RNA was extracted using Qiagen RNeasy
minikits with an on-column DNase digestion. RNA was
quantitated using a Nanodrop® spectrophotometer. RNA
quality was assessed by Nanodrop®, MultiNA microchip
electrophoresis and RT-PCR using GAPDH primers to
test for the presence of genomic DNA. A uniform
amount of RNA of sufficient quality was reverse tran-
scribed using a Qiagen Omniscript kit with added ran-
dom decapentamers and RNase inhibitor (Bioline). Real
time PCR was performed using validated human specificprimers for MMP1, MMP13, ADAMTS4, ADAMTS5,
TIMP1, TIMP3, CD44, PGTS2, IL6, TNF, FN1, ITGA5,
GAPDH, ACAN, COL2A1 and COL1A1 (details in
Additional file 1: Table S1) and internal standards (ran-
dom mix of HSF/HAC cDNA) using a Rotor-gene 6000
(Qiagen) as previously described [24]. The Rotor-gene
6000 Series software (version 1.7) generated relative
fluorescent units (RFU) for sample cycle thresholds based
on calculated, optimized, baseline- and slope-corrected
thresholds generated by tissue-matched cDNA standards.
Results were corrected for total RNA as previously
recommended [25,26] to avoid bias from regulation of
house-keeping genes typically observed in mechanically-
loaded tissues [27], and expressed as fold change from con-
trol (no added HA) cultures of the same patient.
MMP-13 activity and protein levels
Media was harvested and analysed for MMP-13 activity
using a commercially available fluorogenic assay (SensoLyte
Plus™ 520 MMP-13 Assay Kit; Anaspec, San Jose, CA,
USA). MMP-13 activity was measured with and without
activation by aminophenylmercuric acetate (APMA). Fluor-
escence was detected every 30 minutes for 4 hours and
MMP-13 activity reported as change in relative fluorescent
units (RFU)/hour. For Western blot analysis, media was
digested with Streptomyces hyaluronidase (20 turbidity
reducing units/mL at 60°C for 3 hours). Proteins were then
precipitated with 5 volumes of ethanol at 4°C for 16 hours,
redissolved in reducing SDS-PAGE buffer, boiled for 5 mi-
nutes and separated on 10% SDS-PAGE gels (Invitrogen).
Separated proteins were transferred to nitrocellulose mem-
branes and MMP-13 protein detected using a monoclonal
antibody (Abcam 39012) [28,29].
Quantitation of cellular phosphoproteins
Cells for protein extraction were lysed according to the
supplied Bio-plex® protocol. Total protein in all samples
was measured using the bicinchoninic acid assay [30].
Phosphorylated p38 MAPK, JNK and NFκB and total
JNK and p38 MAPK were measured using commercial
kits (Bio-Rad Laboratories) and a Bio-Plex® multiplex ana-
lyser. A kit for quantifying total NFκB on the Bio-Plex®
multiplex analyser was not available at the time these ex-
periments were conducted.
Statistical analyses
Differences in real time PCR results between IL-1β or
HA treatments in HAC or HSF cell cultures were com-
pared using a paired rank sum nonparametric test, as
data was not normally distributed. The fold change from
no treatment (no HA and no IL-1) within each cell type
from each patient was used in order to correct for differ-
ences in baseline expression between the patients. Gene
expression results are presented graphically as a mean
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HA). Bio-plex phosphoprotein and MMP-13 activity
data was analyzed using paired Students t tests between
outcomes in the presence and absence of HA, and un-
paired tests between with and without preincubation. All
analyses were performed using Stata 11.2.Results
Cell viability
Cells remained viable throughout all experiments, with
preliminary trials revealing no change in cell numbers
with any treatment (data not shown) as previously pub-
lished [22]. Some HSF detached from the culture well
surface in the absence of FBS and this phenomenon was
exacerbated in the presence of HA. To prevent this oc-
curring, all HSF studies were carried out in the presence
of 1%(v/v) FBS.Effect of IL-1β, unmodified HA and the amide derivative
of HA on gene expression by chondrocytes
The effects of IL-1 ± simultaneous addition of either HA
preparation on human OA chondrocytes are summarised
in Figure 1 (and Additional file 2: Figure S1). In the ab-
sence of IL-1 stimulation, effects were seen predominantly
with the derivatized compared with unmodified HA, with
the former inducing a 10 fold reduction in IL6 (P = 0.028),
a 4 fold decrease in ADAMTS5 (P = 0.028), and also in-
creasing COL2A1 (P = 0.028) expression by an average of
60% at one or more doses. At the highest dose (1.5 mg/
ml), the amide derivative but not unmodified HA, also
reduced by an average of 45% (range 4 – 75%) the expres-
sion of MMP13 and PGTS2 (P < 0.05). In human OA
chondrocytes IL-1β significantly (P < 0.05) increased ex-
pression of MMP1 (9100 fold), MMP13 (660 fold),
ADAMTS4 (5.5 fold), TNF (21 fold), IL6 (1020 fold),
PGTS2 (180 fold), TIMP3 (76%) and significantly de-
creased expression of COL2A1 (2.6 fold), and ACAN (2
fold). There was no significant effect of IL-1β on chondro-
cyte expression of ADAMTS5, CD44, TIMP1, FN1, ITGA5
or GAPDH. As noted in the absence of IL-1, the
derivatized HA preparation also had a more profound ef-
fect on chondrocyte gene expression than unmodified HA
in IL-1-treated cultures. In addition to significantly redu-
cing IL6 (24 fold), ADAMTS5 (3.5 fold) and increasing
COL2A1 (2 fold) in IL-1-stimulated cultures, the HA
hexadecylamide derivative significantly ameliorated the
IL-1β-induced changes in HAC expression of MMP13
(45%), PGTS2 (11 fold), TNF (2.4 fold), and ACAN (50%)
at one or more of the concentrations tested. Unmodified
HA at 1.0 and 1.5 mg/ml significantly increased further
the IL-1β-augmented expression of TNF and TIMP3 (P =
0.043) but no other genes. The hexadecylamide derivative
of HA increased further the IL-1β-augmented expressionof ADAMTS4 (P = 0.043 at 1.0 mg/ml) but no other
genes.
Effect of IL-1β, unmodified HA and the amide derivative
of HA on gene expression by synovial fibroblasts
The effects of IL-1β and the HA preparations on OA
human synovial fibroblasts (HSF) are summarized in
Figure 2 (and Additional file 3: Figure S2). As in HAC,
effects on HSF in the absence of IL-1 stimulation were
seen predominantly with the derivatized HA compared
with unmodified HA. The hexadecylamide derivative of
HA, but not unmodified HA, at one or more concentra-
tions decreased the expression of TIMP1 (40%), TIMP3
(2.0 fold), IL6 (9 fold) and CD44 (1.7 fold) in the absence
of IL-1β (P < 0.05). Unmodified HA at 1.5 mg/ml and
the amide derivative of HA at all tested concentrations
increased the expression of PGTS2 up to 5.6 fold in the
absence of IL-1β (P = 0.043). IL-1β induced significantly
increased expression of MMP1 (3200 fold), MMP13 (200
fold), ADAMTS5 (8 fold), IL6 (4040 fold), PGTS2 (1090
fold) and significantly decreased expression of COL1A1
(40%) in the synovial fibroblast cultures (P < 0.05). There
was no significant effect of IL-1β on synovial fibroblast
expression of ADAMTS4, CD44, TIMP1, TIMP3, TNF,
FN1, ITGA5 or GAPDH. The derivatized HA preparation
again had a more profound beneficial effect on HSF gene
expression than unmodified HA in IL-1-treated cultures.
Derivatized HA partially but significantly ameliorated the
IL-1β-induced changes in HSF expression of MMP1 (by
70%), MMP13 (40 fold lower), PGTS2 (5 fold lower), IL6
(24 fold lower) and completely reversed the IL-1β-induced
changes in HSF expression of ADAMTS5, TIMP1,
COL1A1 and CD44 (all P < 0.05). Unmodified HA in-
creased further the IL-1β-augmented expression ofMMP1
at 1.0 and 1.5 mg/ml (34%), ADAMTS5 at 0.5 and 1.0 mg/
ml (50%) and IL6 at 1.5 mg/ml (40%) (P = 0.043) in the
HSF cultures. Unmodified HA at all concentrations and
the amide derivative of HA at 0.5 mg/ml significantly in-
creased (60% - 7 fold) HSF ADAMTS4 expression in the
presence of IL-1β (P < 0.05).
Effect of pre-incubation with the amide derivative of HA
on IL-1β-induced gene expression changes
The above data indicated that the derivatized HA had a
pronounced effect on OA chondrocyte and synovial
fibroblast gene expression when added simultaneously
with IL-1. We investigated whether the same or different
effects may be observed if cells were pre-incubated with
HYMOVIS® prior to IL-1 exposure. Figures 3 and 4 (also
Additional file 4: Figures S3 and Additional file 5: Figure
S4) compare the gene expression by HAC and HSF re-
spectively with and without one hour of pre-incubation
with the hexadecylamide derivative of HA before the
addition of IL-1β. Pre-incubation significantly enhanced
Figure 1 HA dose response of HAC gene expression. Dose response of unmodified HA (white markers) and the amide derivative of HA (black
markers) on HAC expression of the indicated genes in the presence (solid line) and absence (dashed line) of IL-1β (2 ng/mL). Values are mean log
fold-change from control (no IL-1 no HA; at zero) from six separate patients. Note different scales within each row. P < 0.05* different from no IL-1
, no HA control; # different from IL-1, no HA control; ‡ different between the amide derivative and unmodified HA at the same concentration.
Smith et al. Journal of Inflammation 2013, 10:26 Page 5 of 16
http://www.journal-inflammation.com/content/10/1/26
Figure 2 HA dose response of HSF gene expression. Dose response of unmodified HA (white markers) and the amide derivative of HA (black
markers) on HSF expression of the indicated genes in the presence (solid line) and absence (dashed line) of IL-1β (2 ng/mL). Values are mean log
fold-change from control (no IL-1 no HA; at zero) from six separate patients. Note different scales between rows. P < 0.05* different from no IL-1,
no HA control; # different from IL-1, no HA control; ‡ different between the amide derivative and unmodified HA at the same concentration.
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Figure 3 Effect of pre-incubation on the HA dose response of HAC gene expression. Dose response on expression of the indicated genes
of the hexadecylamide derivative of HA added simultaneously with (black markers, dashed line) or 1 hour before (white markers, solid line) the
addition of IL-1β (2 ng/mL) in cultures of HAC. P < 0.05 for differences from cultures with IL-1β alone (no added HA; #) or differences +/− pre-
incubation (§). Values are mean log fold-change from control (no IL-1 no HA; black dot) from five separate patients.
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Figure 4 Effect of pre-incubation on the HA dose response of HSF gene expression. Dose response on expression of the indicated genes
of the hexadecylamide derivative of HA added simultaneously with (black markers, dashed line) or 1 hour before (white markers, solid line) the
addition of IL-1β (2 ng/mL) in cultures of HSF. P < 0.05 for differences from cultures with IL-1β alone (no added HA; #) or differences +/− pre-
incubation (§). Values are mean log fold-change from control (no IL-1 no HA; black dot) from five separate patients.




Figure 5 HA dose response on MMP-13 activity and protein.
Dose response of the effect of unmodified HA (black) or the
hexadecylamide derivative of HA (white) on APMA-activated
MMP13 activity in the culture media after exposure to IL-1β (2 ng/mL)
for 24 hours in HSF (A) or HAC (B). P < 0.05 # different from IL-1,
no HA control; ‡ different between the amide derivative and
unmodified HA at the same concentration. (C) Western blot of
MMP-13 protein in pooled media from HAC incubated with and
without unmodified or the hexadecylamide derivative of HA at the
indicated concentrations. Migration of pre-stained molecular mass
markers (kDa) is shown on the left.
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expression of MMP13, IL6 and TNF (P < 0.05) but not
PGTS2 or ADAMTS5. IL-1β-induced MMP1 expression
by HAC was completely reversed by all concentrations
of the hexadecylamide derivative of HA and ADAMTS4
expression was normalized by 0.5 and 1.0 mg/mL
derivatized HA after pre-incubation, whereas simultan-
eous addition of the hexadecylamide derivative of HA
with IL-1β had no effect on these genes (Figure 3). In
contrast to the enhanced effects on HAC, pre-incubation
with the derivatized HA had minimal beneficial effects
compared with simultaneous addition in HSF, significantly
decreasing COL1A1 at the two lower doses and IL6 and
ADAMTS5 at the highest dose (Figure 4).
Effect of blocking CD44 on effects of pre-incubation with
the amide derivative of HA
Addition of anti-CD44 at 5 μg/mL for 1 hour partially
ameliorated (~50%) the inhibition by the derivatized HA
of IL-1-induced IL6 and TNF expression in HAC from
one patient. However this was not statistically significant
and there was no change in the effect of the derivatized
HA on other genes (PTGS2, MMP1, MMP13, ADAMTS4).
There was no change in the effect of the derivatized HA
on gene expression in HAC from another patient when
pre-treated for 3 hours with 10 μg/mL anti-CD44. In HSF
there was a significant reversal by anti-CD44 of the effect
of the hexadecylamide derivative of HA on expression of
MMP13 (P < 0.001) and ADAMTS4 (P = 0.025) in the ab-
sence of IL-1 stimulation (data not shown). However there
was no modulation by anti-CD44 on the effect of HA on
HSF gene expression in the presence of IL-1.
Effect of HA and its amide derivative on MMP-13 protein
and activity
No MMP-13 activity was detected in conditioned media
in the absence of APMA (data not shown), so all subse-
quent results relate to APMA-activated media. Unmodi-
fied HA at all concentrations tested increased MMP-13
activity by 31 – 42% (P < 0.015) in media from HSF (n = 6,
Figure 5A) but no significant effect on this enzyme in
media from HAC (n = 6, Figure 5B) was found, perhaps
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ent patients. The hexadecylamide derivative of HA did not
affect HSF MMP-13 activity but reduced HAC activity by
62% (P = 0.045), 79% (P = 0.006) and 74% (P = 0.006) at
0.5, 1.0 and 1.5 mg/ml respectively (Figure 5B).
Western blotting for MMP-13 in HSF conditioned
media was unsuccessful due to the presence of FBS in
these cultures (data not shown). MMP-13 protein was
immuno-detected in a Western blot of pooled media
from HAC cultured in the presence and absence of
unmodified and the hexadecylamide derivative of HA
(Figure 5C). The migration position in the absence andA
C
E
Figure 6 Effect of HA on HSF phosphoproteins. A) Time course (minute
line) and JNK (white markers, solid line) in HSF after the addition of IL-1β. B
proteins of the hexadecylamide derivative of HA added one hour before (w
line) of IL-1β (2 ng/mL) to cultures of HSF. Cultures were harvested after 30
differences from cultures with IL-1β alone (no added HA; #) or differences
cells from five separate patients.presence of unmodified HA was consistent with pro-
MMP-13 (~60 kDa). In the presence of derivatized HA
the relative molecular mass of the MMP-13 band was
somewhat increased (~65 kDa), and there was a notable
reduction in band intensity in the media of cells cultured
with the highest dose of derivatized HA.
Effect of the hexadecylamide derivative of HA with and
without pre-incubation on nuclear phosphoproteins
Phosphorylation was detectable in culture for 60 minutes
after addition of IL-1β. The HSF and HAC phosphopro-
tein levels peaked at 15 and 30 minutes respectivelyF
D
B
s) of the appearance of phosphorylated p38 (black markers, dashed
) – F) Dose response of the effect on levels of the indicated signalling
hite markers, solid line) or simultaneously with (black markers, dashed
minutes with IL-1β corresponding to peak levels (A). P < 0.05 for
+/− pre-incubation (§). Values are mean % change from IL-1 alone in
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timepoints were subsequently used to measure the ef-
fects of the hexadecylamide derivative of HA on levels
of total and phosphorylated phosphoproteins. Simultan-
eous addition of the hexadecylamide derivative of HA
and IL-1β to either HSF or HAC cultures did not signifi-
cantly alter levels of total JNK or p38 MAPK or phosphor-
ylated JNK, p38 MAPK or NFκB (Figures 6 and 7B-F).
However, IL-1 stimulated levels in HSF of total (P = 0.009;
Figure 6E) and phosphorylated (P = 0.001; Figure 6F)
p38 MAPK decreased by ~50% by one hour pre-
incubation with 1.0 mg/ml derivatized HA. Phosphory-
lated NFκB, total JNK and phosphorylated JNK wereA
C
E
Figure 7 Effect of HA on HAC phosphoproteins. A) Time course (minut
in HAC after the addition of IL-1β. B) – F) Dose response of the effect on l
derivative of HA added one hour before (white markers, solid line) or simu
cultures of HAC. Cultures were harvested after 15 minutes with IL-1β corres
IL-1β alone (no added HA; #) or differences +/− pre-incubation (§). Values aalso significantly reduced by 50% (P = 0.001), 60% (P =
0.024) and 20% (P = 0.024) respectively by this same
treatment (Figure 6B-D). In HSF cultures, the changes in
phosphorylated protein levels induced by pre-incubation
with the hexadecylamide derivative of HA closely
mirrored changes in the total phosphoprotein levels,
suggesting the major effect in this cell type was on total
phosphoprotein. Conversely in HAC, pre-incubation with
all concentrations of the hexadecylamide derivative of HA
significantly decreased the levels of phosphorylated p38
MAPK to less than 30% (P = 0.001; Figure 7F) without
significantly changing total p38 MAPK levels (Figure 7E).
Similarly, pre-incubation with all concentrations of theB
D
F
es) of the appearance of phosphorylated p38 (black) and JNK (white)
evels of the indicated signalling proteins of the hexadecylamide
ltaneously with (black markers, dashed line) of IL-1β (2 ng/mL) to
ponding to peak levels (A). P < 0.05 for differences from cultures with
re mean% change from IL-1 alone in cells from five separate patients.
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the levels of phosphorylated JNK to 30 – 35% (P = 0.001;
Figure 7D) without significantly altering total JNK levels
in HAC (Figure 7C). Phosphorylated NFκB in HAC was
reduced to 22%, 10% and 6% by pre-incubation of HAC
with 0.5, 1.0 and 1.5 mg/mL derivatized HA respectively
(all P = 0.001; Figure 7B).
Discussion
Intra-articular injection of HA is a clinically beneficial
therapy for OA with meta-analysis generally demonstrat-
ing prolonged symptomatic pain relief [2,3]. The mecha-
nisms for this clinical effect remain unclear given the
apparently short half-life of exogenous HA in the joint,
and that long-term modulation of OA disease progres-
sion has not been confirmed in human studies. There is
evidence from animal models to suggest that the benefi-
cial effects of HA may be at least in part dependent on
its molecular weight and potentially its clearance from
the joint [17,18]. We previously demonstrated that a
novel hexadecylamide derivative of HA (HYADD4®-G;
HYMOVIS®) was superior to unmodified HA of the
same initial molecular weight, in terms of reducing
lameness and synovial hyperplasia when administered in
established OA in sheep [5,19], but the mechanisms be-
hind this have not been established.
In the present study we utilized cultures of OA HAC
and HSF derived from total knee replacement patients
with and without added IL-1β, to investigate the molecu-
lar mechanisms whereby the hexadecylamide derivative
of HA may have positive effects on cartilage-degrading ac-
tivities. HAC and HSF from OA joints maintain a patho-
logical phenotype in culture but enhanced pro-catabolic
and pro-inflammatory responses can still be induced by
cytokine stimulation. Although often considered a “non-
inflammatory” joint disease, it is increasingly being rec-
ognized that cytokines, particularly IL-1β, and tumor
necrosis factor-α (TNFα) may play an important role in
both the progressive degradation of the cartilage and
the disease symptoms (reviewed in [31,32]). These cyto-
kines can directly inhibit expression of cartilage extracel-
lular matrix components, stimulate expression of MMPs
and ADAMTS that degrade cartilage, and stimulate the
production of other pro-inflammatory molecules such as
IL-6 and nitric oxide [31-34]. We did not see a stimulation
of ADAMTS5 in these human cells as has been seen pre-
viously in lapine chondrocytes [35], perhaps due to a spe-
cies difference. However the in vitro effects of IL-1 on
ADAMTS5, as with many genes, can vary with cytokine
concentration and incubation time, which may also ex-
plain the differences observed. Interestingly, blockade of
TNFα reduces joint inflammation while inhibition of
IL-1β protects against cartilage degradation in mouse
arthritis models, suggesting the latter may be an attractivemolecular target in the development of disease-modifying
therapies [36]. Studying the effect of therapeutic agents on
HAC and HSF ± IL-1β in vitro may, therefore, provide
insights into potential regulatory pathways and this ap-
proach has been widely used to evaluate other HA formu-
lations [6,16,37-44].
We have demonstrated that the hexadecylamide
derivative of HA had a profound effect in reducing
expression of key proteolytic enzymes implicated in car-
tilage degradation in OA (MMP1, MMP13, ADAMTS4,
ADAMTS5), as well as inflammatory mediators (IL6,
PTGS2) that, as well as regulating chondrocyte and
synoviocyte metabolism, are associated with pain. The
beneficial effects of the derivatized HA did not appear
to be simply through blocking IL-1 from reaching cells,
as there was no effect on the expected regulation of cer-
tain genes by IL-1 e.g. inhibition of ACAN in HAC or
stimulation of ADAMTS4 in HSF. The derivatized HA
was particularly effective at reducing the IL-1β-induced
pro-catabolic and pro-inflammatory gene expression
changes. MMP-13 mRNA, protein and activity levels
were only reduced by the derivatized HA. Furthermore,
the beneficial effects were more pronounced and oc-
curred at a lower dose when the cells (particularly
chondrocytes) were pre-incubated with the HA prior to
IL-1β exposure. This may suggest that IL-1β and HA
are acting via the same signalling pathway, however, HA
pre-incubation may also be inhibiting activity of a “sec-
ondary” IL-1 induced signalling pathway, for example by
blocking an induced collagen peptide binding to ICAM as
recently reported [45]. Taken together this data suggests
mechanisms whereby the hexadecylamide derivative of
HA may have exerted greater inhibition of cartilage de-
generation processes, leading to the beneficial effects in
OA in our previous in vivo studies [5,19].
The turnover of unmodified HA in the joint is rapid,
with a half-life of 27 hours in normal and 11 hours in
inflamed ovine joints [46]. The hexadecylamide deriva-
tive of HA is an non-chemically crosslinked hydrogel
[47] with the capability of completely recovering its
viscoelastic properties after several cycles of mechanical
stress [48] as well as having a prolonged joint residence
time after injection (Fidia SpA, Patent US 7863256). The
increased effect with pre-incubation in the current study
may suggest this derivative of HA acts not only to ameli-
orate existing pathology in cartilage and synovium,
but could, through its prolonged viscoelasticity and
intra-articular retention, prevent the degradative and in-
flammatory changes with future insults. Resistance to
breakdown of the derivatized HA could in part explain
its superior effect compared with unmodified HA, where
only a limited beneficial effect on gene expression in
HAC or HSF ± IL-1β was observed in the current study.
The changes in gene expression induced by the derivatized
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bility as evidenced by the lack of change in cell number,
total RNA yield (data not shown), and GAPDH mRNA in
either cell type, as well as it actually stimulating increased
expression of COL2A1 and ACAN in HAC.
Previous studies have reported significant anti-catabolic
effects of different unmodified HA preparations in cell
and tissue culture [7,16,38,42,43,49,50]. The more limited
effect of unmodified HA in the current study could be as-
sociated with differences between the unmodified HA
preparations evaluated, but also in cell type (human OA,
human RA, chondrosarcoma cell lines), dose of HA used
(e.g. in some publications effects seen only with >2 mg/
ml), and pre-incubation prior to IL-1 stimulation variably
used in previous studies. We observed marked differences
between patients in basal and stimulated gene expression,
as well as the effect of both HA preparations. This could
be due to innate variability in patient demographics (e.g.
age, disease duration, disease severity) or experimental
variability (e.g. topographic differences in sample collec-
tion, adaptability of cells to culture and passage number).
It is plausible that the differences between patients could
reflect the variability observed in those that respond or
not to a given treatment, including intra-articular HA.
Whether this reflects the difference in initial levels of
expression of specific genes could not be examined
adequately with this small subset of patients. Neverthe-
less, the direct comparison between unmodified and
derivatized HA in the same patient cells and paired stat-
istical analysis in the current study enabled us to dem-
onstrate a superior effect of the latter formulation.
There is evidence that the mechanism by which IL-1β
stimulates MMP production in articular chondrocytes
involves phosphorylation of JNK, p38 MAPK and NFκB
[51,52]. Previous studies have shown that HA (800 kDa
and higher) suppressed IL-1β-stimulated production of
collagenases (MMP-1 and MMP-13) by human articular
cartilage explants [15] and isolated chondrocytes [38,42],
as well as a human chondrosarcoma cell line [53], through
down-regulation of phospho-p38 MAPK. In the current
study, pre-incubation of HAC with the hexadecylamide
derivative of HA not only inhibited p38 phosphorylation
but that of NFκB and JNK as well, suggesting all three
pathways may be important in IL-1β-stimulated effects
in chondrocytes. Inhibition of NFκB by HA has been
shown to reduce the production of NO induced by
other factors such as fibronectin fragments in chon-
drocytes [9]. While pre-incubation with derivatized HA
ameliorated JNK, p38 MAPK and NFκB phosphoryl-
ation in IL-1 stimulated HAC, simultaneous addition
did not and there was little or no effect with simul-
taneous or pre-incubation in HSF, despite significant
effects on expression of numerous genes in these
cultures. This suggests the importance of alternatepathways for the derivatized HA in regulating gene ex-
pression in these cells.
In the present study, the derivatized but not unmodi-
fied HA inhibited IL-1-induced MMP13 mRNA expres-
sion in both HAC and HSF. This mRNA regulation was
reflected in the MMP-13 activity measured in the HAC
but not HSF conditioned media. Furthermore, MMP-13
protein in the media detected by Western blotting was
only substantially decreased with the highest dose of
derivatized HA. These apparent discrepancies likely re-
flect the complex regulation of metalloproteinase (MMP
and ADAMTS) activity, whereby transcription, matrix
and cell-surface binding/sequestration, enzyme activa-
tion, inhibitor levels, and enzyme degradation may be
differentially affected by the derivatized HA.
It is unclear whether the enhanced suppression of IL-
1β-induced gene expression changes by the derivatized
compared with unmodified HA, and with its pre-
incubation compared with simultaneous addition, are
due to direct action on IL-1β signalling or secondary to
the enhanced inhibition of IL6 expression. In both HAC
and HSF the changes in expression of MMP13 and
ADAMTS5 with addition of HA ± IL-1β, largely mirror
those of IL6. IL-6 alone has been shown to stimulate
increased ADAMTS and MMP expression and activity
resulting in cartilage degradation [54,55]. Furthermore,
IL-6 is a downstream mediator for the effects of IL-1β on
chondrocyte collagen synthesis [56], and we observed en-
hanced COL2A1 expression by HAC when the derivatized
HA was added simultaneously to cultures ± IL-1β. How-
ever, despite the even greater reduction in IL6 expression
after pre-incubation with the derivatized HA under these
conditions, COL2A1 expression was not significantly al-
tered. The regulation of COL2A1 expression by IL-1β in
chondrocytes involves an increase in the ratio of Sp1 and
Sp3 transcription factors that bind to the COL2A1
promoter region [57]. In contrast, regulation of catabolic
genes (e.g. MMPs, ADAMTS) by IL-1β is largely
dependent on NFκB signalling. It is possible that after pre-
incubation, the amide derivative of HA is still able to regu-
late NFκB but does not affect the Sp1/Sp3 levels and this
would be interesting to examine in future studies.
It is not clear why the effect of pre-incubation with
the amide derivative of HA on IL-1β-stimulated expres-
sion was greater in HAC than HSF. HAC and HSF did
have a distinct response to IL-1β, as seen with the differ-
ential upregulation of ADAMTS4 and ADAMTS5 in the
two cell types. Furthermore, the response of HSF to IL-1β
was approximately 10× greater than HAC with respect to
fold increase in MMP expression. Therefore it may be that
higher doses of HA or longer pre-incubation may be re-
quired for complete inhibition in HSF. As HSF are exposed
to greater concentrations of HA within the joint than
HAC, they may be less susceptible to exogenous HA-
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complement of HA receptors and signalling mechanisms.
CD44 is a multivariate transmembrane glycoprotein
known to be the major cell surface receptor for HA, and
HA/CD44 interaction plays a central role for the pro-
tective effects of HA in various cell types [58-60]. CD44
is abundantly present in the synovium [61] and synovial
fluid [62] of the joints of patients with OA, and levels
correlate with the degree of inflammation, although not
with the degeneration state of the articular cartilage [62].
The interaction of unmodified HA with CD44 is import-
ant in suppression of IL-1β-stimulated effects in cul-
tured chondrocytes [15,38,42,53] and synovial fibroblasts
[49]. CD44 is also involved in the stimulation of OA
chondrocyte proliferation by the amide derivative of HA
[22]. We were able to demonstrate amelioration of a few
of the effects of the derivatized HA on gene expression
using a CD44 blocking antibody in confluent cultures of
HAC and HSF supporting a role for this cell-surface re-
ceptor. However regulation of expression of most genes
by the derivatized HA, particularly in the presence of IL-
1 was not altered by blocking CD44 in the current stud-
ies. Expression of CD44 was significantly decreased by
derivatized HA in both HAC and HSF (Additional file 4:
Figure S3), which may contribute to the limited effect of
blocking this cell surface receptor. Taken together this
may suggest the importance of alternate pathways, such
as via ICAM [45,63], for the derivatized HA in regulat-
ing IL-1-induced gene expression changes in these cells.
Conclusions
The present studies have demonstrated several potential
key mechanisms whereby the intra-articular injection of
a hexadecylamide derivative of HA may have both symp-
tom and disease-modifying effects in OA. The superior
beneficial effects of the derivatized compared with un-
modified HA on both chondrocyte and synovial fibroblast
expression of catabolic enzymes and inflammatory cyto-
kines/mediators, were consistent with the previously de-
scribed positive benefits in a large animal model of OA. It
remains to be determined whether this hexadecylamide
derivative of HA will be superior to other unmodified
preparations of HA in clinical trials.
Additional files
Additional file 1: Table S1. Real time PCR primers to human genes
used in this study.
Additional file 2: Figure S1. HA dose response of HAC gene
expression. Dose response of unmodified HA (white markers) and the
hexadecylamide derivative of HA (black markers) on HAC expression of
the indicated genes in the presence (solid line) and absence (dashed
line) of IL-1β (2 ng/mL). Values are mean log fold-change from control
(no IL-1 no HA; at zero) from five separate patients. P < 0.05* different
from no IL-1, no HA control; # different from IL-1, no HA control;‡ different between the amide derivative and unmodified HA at the
same concentration.
Additional file 3: Figure S2. HA dose response of HSF gene
expression. Dose response of unmodified HA (white markers) and the
hexadecylamide derivative of HA (black markers) on HSF expression of
the indicated genes in the presence (solid line) and absence (dashed
line) of IL-1β (2 ng/mL). Values are mean log fold-change from control
(no IL-1 no HA; at zero) from five separate patients. P < 0.05* different
from no IL-1, no HA control; # different from IL-1, no HA control;
‡ different between the amide derivative and unmodified HA at the
same concentration.
Additional file 4: Figure S3. Effect of pre-incubation on the HA dose
response of HAC gene expression. Dose response on expression of the
indicated genes of the hexadecylamide derivative of HA added
simultaneously with (black markers, dashed line) or 1 hour before (white
markers, solid line) the addition of IL-1β (2 ng/mL) in cultures of HAC.
P < 0.05 for differences from cultures with IL-1β alone (no added HA; #)
or differences +/− pre-incubation (§). Values are mean log fold-change
from control (no IL-1 no HA; black dot) from five separate patients.
Additional file 5: Figure S4. Effect of pre-incubation on the HA dose
response of HSF gene expression. Dose response on expression of the
indicated genes of the amide derivative of HA added simultaneously
with (black markers, dashed line) or 1 hour before (white markers, solid
line) the addition of IL-1β (2 ng/mL) in cultures of HSF. P < 0.05 for
differences from cultures with IL-1β alone (no added HA; #) or differences
+/− pre-incubation (§). Values are mean log fold-change from control (no
IL-1 no HA; black dot) from five separate patients.
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